Holmes RA: [153Sm] EDTMP: A potential therapy for bone cancer pain. Semin Nucl Med22:41-45, 1992
2.
Lattimer JC, Corwin LA, Stapleton J., et al: Clinical and clinicopathologic response of canine bone tumor
3.
patients to treatment with samarium- 153EDTMP. J Nucl Med31:1316-1325, 1990
4.
Lattimer JC, Corwin LA, Stapleton J., et al: Clinical and clinicopathologic effects of samarium-153-EDTMP administered intravenously to normal beagle dogs. J Nucl Med31:586-593, 1990
5.
Singh A., Holmes RA, Farhangi M., et al: Human pharmacokinetics of samarium- 153-EDTMP in metastatic cancer. J Nucl Med30:1814-1818, 1989
6.
Turner JH, Martindale AA, Gorby P., et al: Samarium-153-EDTMP therapy of disseminated skeletal metastases . Eur J Nucl Med15:784-795, 1989
7.
Bayouth JE, Macey DJ, Kasi LP, et al: Dosimetry and toxicity of 153-Sm-EDTMP administered for bone pain due to skeletal metastases. J Nucl Med35:63-69, 1994
8.
Eary JF, Collins C., Stabin M., et al: Samarium-153-EDTMP biodistribution and dosimetry estimation . J Nucl Med34:1031-1036, 1993
9.
Holmes RA, Farhangi M.: Dose tolerance of Sm-153-EDTMP in metastatic bone cancer. Proceedings of the 35th Annual Meeting. J Nucl Med 29:775, 1988 (abstr)
